Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season
about
Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza virusesEvolution of the receptor binding properties of the influenza A(H3N2) hemagglutininReverse Genetics Approaches for the Development of Influenza VaccinesDetection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus cultureA synthetic adjuvant to enhance and expand immune responses to influenza vaccinesThe substantial hospitalization burden of influenza in central China: surveillance for severe, acute respiratory infection, and influenza viruses, 2010-2012.Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses.Turkey versus guinea pig red blood cells: hemagglutination differences alter hemagglutination inhibition responses against influenza A/H1N1.Cellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects.Influenza virus surveillance in Argentina during the 2012 season: antigenic characterization, genetic analysis and antiviral susceptibility.Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicityPlant-made vaccines in support of the Millennium Development Goals.Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.N-linked glycosylation in the hemagglutinin of influenza A viruses.Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009.Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?Integrating influenza antigenic dynamics with molecular evolutionMolecular epidemiology of influenza A/H3N2 viruses circulating in Uganda.Serologic assays for influenza surveillance, diagnosis and vaccine evaluation.Temporally structured metapopulation dynamics and persistence of influenza A H3N2 virus in humans.Canalization of the evolutionary trajectory of the human influenza virusRecent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analysesWHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 201Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories.Antibody landscapes after influenza virus infection or vaccination.Development of a neutralization assay for influenza virus using an endpoint assessment based on quantitative reverse-transcription PCRClinical profiles associated with influenza disease in the ferret modelPotential of the test-negative design for measuring influenza vaccine effectiveness: a systematic reviewClinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccinationMolecular epidemiology and phylogenetic analyses of influenza B virus in Thailand during 2010 to 2014.Molecular characterization of influenza viruses collected from young children in Uberlandia, Brazil - from 2001 to 2010.Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses.Targeting B cell responses in universal influenza vaccine design.Identification of H5N1-specific T-cell responses in a high-risk cohort in vietnam indicates the existence of potential asymptomatic infections.Antigenic distance measurements for seasonal influenza vaccine selection.Multi-Dimensional Measurement of Antibody-Mediated Heterosubtypic Immunity to Influenza.Generation and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation.Influenza Seasonality in the Tropics and Subtropics - When to Vaccinate?Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.
P2860
Q24615003-D29A51F3-F984-4407-9C03-F455CE3AD170Q27675474-E715129D-E73A-4670-AEC0-5BE1586AA1B4Q28076140-AD5EF224-C61E-4994-BCC3-9435F2E61B0FQ28659731-5E2AB8BD-D01E-4329-9D5E-8D8C4A247CD7Q28748680-4CACB4EE-E15C-449A-85D8-E95B4063A3CEQ30355388-FC32ED02-C5CE-4843-9A4E-6D4DD40E0690Q30356476-A0567A08-EDB0-4A03-BBEE-174879176417Q30362094-9261DECF-61D4-4BF8-BB8C-76DCDB2EB791Q30366119-EE23B8F4-C9D9-47D8-B57A-67F6ED8EF048Q30378860-236C97FE-73CF-4969-A29C-BF9FAA4E47EAQ30382921-47EA870B-2AF4-44AF-8D7D-6CBEF67F945AQ30396217-2C39B8DC-68A0-4B37-B1DA-B3E8FD93AED8Q30396654-37241CD8-7E0F-4437-9336-663720E521DFQ30420126-FA7C6E08-9E3E-4C4E-8BDC-0DAB4CF949C9Q33698062-3A8FF18F-8738-40FF-A86E-80963228AF28Q33869689-F10F1881-7169-4905-8DAD-D5BD476FCC7FQ33990541-A5725CD0-FCA1-4414-8D58-96B3A732B6E7Q34039764-0E325801-A378-4D4F-AFA5-A84A18ABD98FQ34087884-166045D8-1B78-4B3B-83F2-F6CD5F0683B6Q34194336-224A3367-092F-4149-AD26-7E49C8989FFAQ34232682-70F8BDE7-8F21-4007-AE5F-BC75876C21CBQ34252070-AB1A5ACC-43D5-4E31-9C38-72A1169C8700Q34262280-736D7C77-9EFC-4DEC-A1E4-5CD85328B7FFQ34295635-F34B3393-DDE3-4AD2-BA46-B66C1550B7DAQ34332806-0F11FE2D-8F1C-4382-997C-F6CC32BF5C5EQ34580640-1BD0B630-C8AF-471E-9757-C00A8038E143Q34598349-CE794461-E278-40C7-B6BF-62F405522500Q34614939-42B40784-4600-4DE2-823C-DBE871BF757FQ34778408-E9D5AD85-2C0F-4D65-89E8-3D2701B30C23Q34970364-62ECA625-CABF-4A43-84A1-CDAD5C39766AQ34989377-09DAF000-F221-4382-A214-BB65A69BAC08Q35108539-2DA6B2ED-B4E6-4D81-8105-72E6DDFBA5BFQ35235777-E545EF44-EBDB-4AD1-B382-99C3CE87D3D5Q35540405-D71E9841-7B50-4DE7-A0BF-59B4EFFA4085Q35623722-841EB2F5-ADFF-4CBD-9FA4-C5158F6A1867Q35633954-6FA5CD6E-6ED1-470F-A1E0-33AAF2CC15E0Q35671981-DB7EFEB2-7D39-42A7-B35C-6A25FB41E213Q35787563-C837EF9C-41DA-4C0B-90EE-94E1E9CCDA5BQ36000802-71633426-A358-44C7-9411-2F44B848D01AQ36075789-BB33F7EE-95C6-468A-A40C-C955A9CB6018
P2860
Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season
description
article
@en
im Dezember 2009 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2010
@uk
name
Epidemiological, antigenic and ...... 010 Northern Hemisphere season
@en
Epidemiological, antigenic and ...... 010 Northern Hemisphere season
@nl
type
label
Epidemiological, antigenic and ...... 010 Northern Hemisphere season
@en
Epidemiological, antigenic and ...... 010 Northern Hemisphere season
@nl
prefLabel
Epidemiological, antigenic and ...... 010 Northern Hemisphere season
@en
Epidemiological, antigenic and ...... 010 Northern Hemisphere season
@nl
P2093
P50
P921
P1433
P1476
Epidemiological, antigenic and ...... 010 northern hemisphere season
@en
P2093
Alexander Klimov
Derek Smith
Gary Grohmann
John McCauley
Keiji Fukuda
Masato Tashiro
Rod Daniels
P304
P356
10.1016/J.VACCINE.2009.11.043
P407
P577
2009-12-09T00:00:00Z